Combined Metabolic Activators Accelerate Symptom-Free Recovery in COVID-19

Impact of Severe COVID-19

In severe cases, COVID-19 can result in respiratory issues, metabolic dysfunction, heightened inflammation, and organ failure. Research indicates that metabolic abnormalities and hyper-inflammation are linked to deficiencies in nicotinamide adenine dinucleotide (NAD+) and glutathione (GSH) metabolism. The depletion of NAD+ and GSH has been connected to increased mortality rates among COVID-19 patients.

Current Treatment Approaches

Patients with COVID-19 are currently treated for mitochondrial dysfunction and metabolic abnormalities using antiviral medications such as Remdesivir and Favipiravir. However, exploring new treatment methods that complement existing therapies could be beneficial.

Introduction to Combined Metabolic Activators

Combined metabolic activators (CMAs) show promise as potential treatments for non-alcoholic fatty liver disease, lung diseases, and viral infections. These activators include L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate, all known for their role in enhancing mitochondrial function. Given their association with improved metabolic conditions, researchers considered that CMAs might facilitate recovery from COVID-19 by boosting levels of NAD+ and GSH.

Research Findings on Combined Metabolic Activators

Recent investigations have focused on the efficacy of CMAs in mild-to-moderate COVID-19 cases. A randomized, double-blind, phase three clinical trial evaluated the safety, tolerability, and effectiveness of CMAs, specifically glutathione and NAD+ precursors, in treating COVID-19.

The study involved 304 adult patients experiencing COVID-19. The most frequently reported symptoms included muscle or joint pain (61%), fatigue (50%), cough (43%), headache (38%), fever (28%), and sore throat (24%). Participants received either a placebo or metabolic activators, administered twice daily, alongside standard care.

Results of the Study

The findings revealed that the administration of CMAs led to significant advancements in recovery:
– Reduced recovery time by an average of 3.5 days (from 9.2 days in the placebo group to 5.7 days in the CMA group)
– Improved overall clinical health among all participants
– Decreased inflammation levels indicated by inflammatory markers
– Enhanced liver health

These results suggest that combined metabolic activators are a safe and effective treatment option for patients with mild-to-moderate COVID-19, enhancing clinical outcomes by improving immune responses and regulating antioxidant, amino acid, and lipid metabolism.

Expert Insights

Senior researcher Dr. Adil Mardinoglu noted, “Our phase three data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19. Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”

References

1. Altay O, et al. (2021). Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19. Adv. Sci. Retrieved from: https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222
2. COVID-19 patients recover faster with metabolic activator treatment, study shows (2021). EurekAlert! Retrieved from: https://www.eurekalert.org/pub_releases/2021-06/krio-cpr062821.php
3. Image by Miguel Á. Padriñán from Pixabay